Masimo Corporation

NASDAQ:MASI

Medical - Devices

Healthcare
$179.95 +0.00%

+$0.00 today

Market cap
$9.42B
Beta
1.10
P/E (TTM)
123.1
EPS (TTM)
$1.46
52W Low $125.94High $179.99

Volume 0.00M

Average 1.08M

MASI Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Masimo CorporationNASDAQ: MASI

Capital Expenditures · Q1 FY2026 · quarter ended Apr 2026

Capital expenditures growth accelerates

Q1 FY2026 capital expenditures of $5.3M (cash outflow) rose 29.3% year over year, ahead of the -47.9% change in trailing-twelve-month capital expenditures. Sequentially, it fell 25.4% from the prior quarter. Over 3 fiscal years it compounded at -29.9% a year.

Context

  • Capital expenditures amounted to 1.3% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +29.3% holds above the trailing-twelve-month pace of -47.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterApr 2026
-$5.3M-25.4% QoQ
Last fiscal yearJan 2026
-$19.4M-62.0% YoY
LTMApr 2026
-$23.2M-47.9% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.3%——
1 year-62.0%——
3-year CAGR-29.9%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(19.4M) USD
Year-over-year change
+62.0%

Capital Expenditures vs competitors

How MASI compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -47.9% is the 9th highest of 10, against a peer median of -7.9%.
  • Capital expenditures amounts to 1.5% of revenue for MASI, versus a peer median of 3.1%.
MASI Competitors
Capital Expenditures for MASI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BAXBaxter International Inc.LTM Jun 2026$641M USD+48.4%-6.3%5.6%
ATRAptarGroup, Inc.LTM Jun 2026$273.09M USD-0.6%-5.0%6.9%
STVNStevanato Group S.p.A.LTM Jun 2026€272.65M EUR-38.5%+1.4%22.3%
HSICHenry Schein, Inc.LTM Jun 2026$161M USD+4.5%+13.1%1.2%
AVTRAvantor, Inc.LTM Jun 2026$142.3M USD+13.0%-1.2%2.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$139.5M USD-25.3%+11.3%5.4%
MOHMolina Healthcare, Inc.LTM Sep 2026$93M USD-17.7%+3.5%0.2%
RGENRepligen CorporationLTM Jun 2026$24.09M USD-7.9%-43.9%3.1%
MASIMasimo CorporationLTM Apr 2026$23.2M USD-47.9%-29.9%1.5%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$1.45M USD—-39.4%0.5%
ABVXAbivax S.A.FY2025€136.4K EUR-78.8%-25.0%—
Peer median (excluding MASI) —-7.9%-3.1%3.1%

Competitors are the stored peer set for MASI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Jan 2026
Net Income229.6M143.5M81.5M(304.9M)(151.5M)
Depreciation & Amortization35.6M136.1M98.3M103M38.8M
Deferred Income Tax(15.1M)(39.3M)(35.6M)(38.2M)11.8M
Stock-Based Compensation44.7M47.7M7M41.5M35.8M
Change in Working Capital(31.5M)(261.8M)(70.9M)(10.7M)(89.9M)
Accounts Receivables(76.9M)(151.3M)91.9M(60.2M)17.2M
Inventory13.5M(155.9M)(69.2M)(7.5M)(112.1M)
Accounts Payables11M60.5M(19.6M)14.8M(27.1M)
Other Working Capital20.9M(15.1M)(74M)42.2M32.1M
Other Non-Cash Items1.3M3.2M13.8M405.7M372.2M
Operating Cash Flow264.6M29.4M94.1M196.4M217.2M
Capital Expenditures(34.9M)(56.3M)(87.7M)(51.1M)(19.4M)
Acquisitions (Net)0(999.7M)7.5M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(12M)(5.2M)(44.7M)(31.2M)294.5M
Investing Cash Flow(37.5M)(1.06B)(81.2M)(51.2M)275.1M
Debt Repayment0939.2M(51.2M)(146.8M)(207.8M)
Common Stock Issued23.2M8.1M7M25.2M71.4M
Common Stock Repurchased(128.9M)(401.5M)00(363.7M)
Dividends Paid00000
Other Financing Activities(16.7M)(25.4M)(12.9M)(4M)(20.6M)
Financing Cash Flow(122.4M)520.4M(57.1M)(125.6M)(520.7M)
Effect of Forex Changes(1.3M)(30.9M)2.8M(6.4M)53.8M
Net Change in Cash103.4M(538.8M)(41.4M)13.2M26M
Free Cash Flow229.7M(26.9M)6.4M145.3M197.8M

Masimo Corporation

NASDAQ:MASI

Intrinsic Alpha fair value

Locked

Current Price

$179.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.